Tuberculosis (TB) infection of bones and joints accounts for 6.7% of TB cases in England, and is associated with significant morbidity and disability. Public Health England reports that patients with TB experience delays in diagnosis and treatment. Our aims were to determine the demographics, presentation and investigation of patients with a TB infection of bones and joints, to help doctors assessing potential cases and to identify avoidable delays.
Since 2011, there has been a year-on-year decline in the incidence of tuberculosis (TB) in England, with the number of cases falling from 15.6 per 100 000 (8280 cases) in 2011 to 10.5 per 100 000 (5758 cases) in 2015. The proportion of extra-pulmonary cases has remained constant (46.6% in 2015), and is higher in patients who have been born outside the United Kingdom (53.1% of total cases) compared with those who are born in the United Kingdom (30.1%). Bone and joint TB, which includes spinal disease, accounts for 6.7% of all TB cases in England and 14.4% of the extra-pulmonary cases.
1 Bone and joint TB is associated with significant morbidity including chronic pain, deformity and disability so early diagnosis and treatment is desirable. 2 Delays of weeks before starting anti-TB treatment are common. In England, 28% of patients with pulmonary TB have delays of > four months between the onset of symptoms and starting treatment. 1 European studies of spinal TB also report diagnostic delays. [3] [4] [5] Bone and joint TB is rarely seen by surgeons, particularly in non-specialist centres. Only 386 cases were notified in England in 2015.
1 Inexperience with its clinical presentation and diagnostic work-up, and its varied presentation at different anatomical sites, means that there may be long delays in starting treatment in many of these patients, which in turn risks clinical deterioration and worsening disability. 6 We performed this retrospective observational study of bone and joint TB aiming to describe the typical demographics, presentation and investigation of these patients, to help doctors assessing potential cases. We investigated the clinical pathways through which the diagnosis was confirmed and treatment started, aiming to identify avoidable delays.
Patients and Methods
This study was conducted at a large specialist orthopaedic hospital in the United Kingdom (Royal National Orthopaedic Hospital NHS Trust) that includes a regional Sarcoma Unit. Bone and joint samples were cultured for TB using the BACTEC MIGIT system (BD, Franklin Lakes, New Jersey). Rapid Polymerase Chain Reaction (PCR) based testing was performed locally using the Xpert MTB/RIF (Cepheid, Sunnyvale, California) assay where requested. Suspected myco-bacterial isolates from culture were sent to Public Health England's (PHE) Myco-bacterial Reference Laboratory for confirmation, speciation and sensitivity testing.
We included all patients aged > 18 years who had pathological specimens taken between June 2012 and May 2014 that grew Myco-bacterium tuber-culosis (Mtb). Patients were identified using the laboratory information management system WinPath,(CliniSys Solutions Ltd, Chertsey, United Kingdom). Paper and electronic records were accessed with appropriate permission. A standardized proforma recorded demographics, clinical presentation, radiological findings, histopathology, and important dates including the presentation, referral to the orthopaedic centre, biopsy, results, communication of results to the GP and/or referring hospital, referral to TB services and commencement of anti-TB medication. Data were anonymized and recorded in Microsoft Excel 2010 (Microsoft, Redmond, Washington). Statistical analysis. Data were analyzed using Excel 2010 and GraphPad 2017 (GraphPad Software, Inc. San Diego, California). After descriptive study of the different variables, a Mann-Whitney U test was used for comparison of medians. Tests were two-tailed; a p-value of < 0.05 was considered significant.
Results
During the study period, cultures from 31 adult patients were positive for TB. All were sensitive to the first line antibiotics Rifampicin, Isoniazid, Pyrazinamide and Ethambutol. The median age of the patients was 37 years (inter-quartile range (IQR) 29 to 53) and 21 were men (68%). Of the 28 patients for whom country-of-birth was recorded, 25 (89%) were born outside the United Kingdom, pre-dominantly in southern Asia (Table I) , living in the United Kingdom for a median of six years at the time of diagnosis (IQR 3.5 to 14). Three were born in the United Kingdom; their median age was 41 (range 29 to 85); their self-reported ethnicities were 'Black -Other', 'Pakistani' and 'White British' and. No patients were known to have the Human Immunodeficiency Virus (HIV) prior to diagnosis. One was found to be HIV negative at the orthopaedic centre. All were referred to the local TB services where HIV testing is routine for patients with newly diagnosed TB as per national guidance. These results were not available to the orthopaedic centre and so are not included.
The most commonly affected sites were joints (ten; 32%) and the spine (eight; 26%), followed by long bones (six; 19%) and axial bones (four; 13%). Multifocal disease, defined as more than one anatomical site (bones, joints, pulmonary or elsewhere), was present in eight patients (26%), six of whom had spinal involvement (Table II) ; none had pulmonary disease. Commonly reported symptoms were pain (94%; 29/31) and swelling (93%, 26/28), but 'typical' TB 
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Time between symptom onset and referral to specialist centre < 6 mths (n) ≥ 6 mths (n) Unknown (n) India 5 3 3 P a k i s t a n 1 1 4 United Kingdom 0 3 0 A f g h a n i s t a n 0 symptoms were uncommon: 21% (3/14) reported fever, 14% (2/14) night sweats and 56% (9/16) weight loss. Few were asked about TB contacts (7/31) or past infection (1/31 patients); three reported a TB contact; one reported a previous TB infection. The median time between the onset of symptoms and starting anti-TB treatment was nine months (IQR 6 to 20, n = 26) with 38% (10/26) waiting > one year. We examined the referral, diagnosis and treatment pathways in further detail to identify potentially avoidable areas of delay. The median time from the onset of symptoms to referral to the tertiary centre was seven months (IQR 3 to 13.5; n = 21). There were insufficient data to establish what proportion of this time was attributable to the patient not seeking medical advice, and what proportion was spent being managed in primary or local secondary care. A total of 28 patients (90%) were referred via the sarcoma pathway and all of these were seen within two weeks of the referral being received by the centre. Referral data were available for two of the three non-sarcoma referrals; they were seen 27 and 33 days after referral, respectively. The median time between the centre receiving the referral and the patient starting anti-TB treatment was 2.4 months (IQR 1.7 to 3.7, n = 30); 33% (10/30) waited > three months; 10% (3/30) waited > six months.
After clinical review, 30 patients (97%) underwent MRI. It was contra-indicated in one patient who had a CT scan. In 26 (84%), the radiologist included TB in the differential diagnosis. All patients underwent a biopsy: 29 (93%) had specimens sent for histopathology and 24 (77%) for TB culture. Seven patients' samples from the first biopsy (23%) were not sent for TB culture; TB was suspected in five of these; all seven required a second biopsy. The median time to the second biopsy was 39 days (IQR 19 to 52).
Granulomas were seen in 87% (20/23) of the histopathology samples; no acid-fast bacilli (AFB) were seen. TB cultures were positive in 92% (22/24) of the first biopsies. The median time to the identification of a positive culture was 22 days (IQR 16 to 38, n = 31), plus ten days (IQR 9 to 16, n = 31) for confirmation of Mtb species. Xpert MTB/ RIF was performed on five patients' samples, taking two days from biopsy to results (IQR 2 to 7); four tested positive for Mtb and negative for rifampicin-resistance. One patient started anti-TB treatment before the biopsy; for the remaining 30 patients, those whose samples were tested with Xpert MTB/RIF waited significantly less time from the diagnostic biopsy to starting treatment than those whose samples were not tested (median of eight days with Xpert MTB/RIF, n = 5 versus 36 days without, n = 25, p = 0.016).
Anti-TB treatment was started in 13 patients prior to the identification of a positive culture. For the remaining 18, the median time from this identification to starting treatment was 20 days (IQR 9 to 33). Of these 18, ten were referred onwards before a positive culture had been identified (five to a TB clinic, four to the GP, one to a referring hospital). The time between referral and starting treatment was available for four of six patients who were referred after cultures grew TB: the median time was four days for the three referred directly to the TB clinic; one patient was referred to the GP and waited 49 days before starting treatment in a TB clinic. 
Discussion
Diagnosing bone and joint TB is challenging and there is no specific national guidance on the optimal diagnostic pathway. In this study of culture-positive patients with bone and joint TB, they waited a median of nine months between the onset of symptoms and starting anti-TB treatment, substantially longer than the national median for pulmonary cases of 74 days 1 and longer than reported in previous European studies on spinal TB. [3] [4] [5] Seven of these months were before referral to the specialist centre. We could not determine what proportion of this time was attributable to delays in patients seeking medical advice, as reported elsewhere, 7 and what time was attributable to them being managed within primary and secondary care, but the non-specific clinical presentation of bone and joint TB is likely to have been a contributing factor. Omitting to send biopsy specimens for TB culture contributed a further median of five weeks to the delays. Waiting for the results of TB culture took three to four weeks, and not referring directly to the TB clinic may have also contributed to delays. Maintaining a high index of suspicion, the targeted use of rapid molecular tests, and direct referral to TB services should reduce the delay to the start of treatment in these patients.
In this cohort, patients were typically young male migrants from southern Asia. This is in keeping with national data from PHE: 73% of patients diagnosed with TB in 2015 were born outside the United Kingdom, most commonly in India, Pakistan, and Bangladesh.
1 Previous studies on bone and joint TB in low-endemic countries report varying proportions of cases occurring in immigrants, with some centres reporting high proportions (92% United Kingdom; 3 83% Denmark, 8 66% The Netherlands) 9 and others in France 10 and Spain 5 reporting much lower figures. The country of origin of the affected immigrants varies in these studies, reflecting differing trends of migration.
Few patients presented with 'typical' TB symptoms including fevers and night sweats; just over half reported weight loss. Non-specific symptoms of pain and swelling were common. This is consistent with previous studies meaning that clinicians cannot rely on the presentation alone to suggest underlying TB. 3, 5, 8 Maintaining a high index of suspicion and knowledge of local epidemiology and high-risk groups are essential to ensure that the necessary microbiological tests are requested and the diagnosis is not missed.
The spine is usually the most common site of bone and joint TB, accounting for 65% of bone and joint infections in PHE data 1 and 54.3% in a Danish cohort 8 , but only 26% of our patients had spinal involvement. This distribution probably reflects the fact that 90% were referred via the sarcoma pathway and the centre does not take emergency admissions. Clinically, TB can mimic sarcoma: both can be insidious in onset, affect younger adults and present with pain and swelling. 11 European studies have reported that up to 35% of patients with bone and joint TB have concomitant pulmonary TB. 3, 8, 10 While 26% of our patients had multifocal disease, none had pulmonary involvement. Acutely unwell patients with pulmonary involvement would have presented through other pathways and would not have been included in this study.
In most cases, radiological and histopathological findings suggested underlying TB. MRI was useful, with TB being considered in 83% of MRI reports. Data showing what proportion of radiology reports mention TB in the differential diagnosis were not available. The radiological features of bone and joint TB are diverse and non-specific. In the spine, TB usually affects several vertebral bodies and adjacent discs; paraspinal abscesses are common. Vertebral collapse and anterior wedging are seen in advanced infection. Infection of the bone causes chronic osteomyelitis with non-specific radiological features. TB arthritis resembles other infectious and inflammatory arthritides. 2, 12 Typical histopathological features of TB include granulomas and AFBs. 13 Granulomas were often seen in this study. Their presence provides strong evidence of TB, which is particularly useful when cultures are negative. Conversely, AFBs were not seen in any of our patients. They are visible only when the myco-bacterial burden is high and affected by formalin, so their absence should not deter the clinician from diagnosing TB.
Every patient in this study underwent a biopsy, but 23% did not have samples sent for mycobacterial culture, despite TB being in the differential diagnosis for most of them. All seven needed a second biopsy, waiting a median of five weeks for the procedure. Biopsy is crucial for confirming the diagnosis of TB. All efforts should be made to obtain and send specimens for histopathological and microbiological investigations. Microbiological specimens must not be sent in formalin, 14 which sterilises any organisms present. National Standards for Microbiology recommend that routine mycobacterial culture is considered for all non-postoperative spinal infections. 15 We recommend that mycobacterial culture is requested for any patient in whom infection or malignancy is suspected, or where there is clinical uncertainty. This recommendation has been implemented in local policy since the study period.
Mycobacterial culture is essential for obtaining anti-TB drug susceptibilities and is another reason for performing a biopsy whenever possible. While no patients in this study had drug-resistant strains, 7.4% of TB infections in England are reported to be resistant to at least one firstline antibiotic and 1.3% are 'multi-drug resistant', meaning the isolate is resistant to both isoniazid and rifampicin.
1 Worldwide, 5% of TB cases are multi-drug resistant, with rates > 20% in some ex-Soviet states. 16 In England, most multi-drug resistant TB cases are diagnosed in immigrants from Latvia (20%) and Lithuania (23.9%).
1
While mycobacterial culture remains the gold standard for diagnosing TB, 17 its primary disadvantage is the time it takes to grow TB. The median time to the identification of a positive culture in this study was 22 days. Five patients' samples were tested with Xpert MTB/RIF; 80% returned a positive result, with a median turnaround time of two days. Those whose samples were tested with Xpert MTB/RIF waited four weeks less from the time of biopsy to starting treatment than those whose samples were not tested. Xpert MTB/RIF is a PCR-based assay that can provide the diagnosis of TB within a few hours. It was initially developed for use with sputum to diagnose pulmonary TB, where its sensitivity approaches 100% for smear-positive disease. 18 The World Health Organisation recommends Xpert MTB/ RIF for testing samples in patients suspected of having extra-pulmonary TB. 19 Its sensitivity in tissue ranges from 77% to 95% (specificity 96% to 98%) when compared with myco-bacterial culture, with the highest sensitivities in samples from lymph nodes. In pus, sensitivities range from 75% to 96% (specificity 94% to 100%); lower sensitivities are reported with fluid samples (sensitivity 19% to 81%). 20, 21 In bone and joint TB studies, sensitivities of 96% (spinal TB in South Africa) 22 and 100% (bone and joint TB in China) 23 have been reported. Xpert MTB/RIF also rapidly detects rifampicin-resistance with a sensitivity approaching 100%, 18 making it an invaluable tool when investigating patients from high-risk countries for multidrug resistant TB.
GenoType MTBDRplus (Hain Lifescience GmbH, Nehren, Germany) is another molecular test that can provide rapid confirmation, within two to three days, of the presence of Mtb DNA and common mutations associated with resistance to rifampicin and isoniazid. Reported sensitivities in pulmonary samples are comparable with Xpert MTB/RIF. 24 In the Chinese bone and joint TB study, sensitivity was 87.5% for culture-confirmed cases and 63.6% for culture-negative 'probable' cases. 23 Almost all hospitals have access to Xpert MTB/RIF and GenoType MTBDRplus, although most microbiology departments do not offer it 'in-house'. 25 The positive predictive value of the test is affected by the prevalence of TB. Therefore, in countries with a low prevalence, such as the United Kingdom, they should not be used indiscriminately, due to the risk of false-positive results. Where clinical suspicion, and therefore pre-test probability is high, their use can reduce the time to diagnosis and to starting treatment from weeks to days. Doctors who request these investigations should be aware of the possibility of false-negatives and should not be deterred by a negative PCR in a high-risk patient. We recommend considering rapid molecular testing for samples from all patients where bone and joint TB and sarcoma are in the differential diagnosis and our local policy is changing to reflect this. Given the importance of targeted testing with these assays and their interpretation, we recommend a formal consultation with a TB or infection specialist where TB is suspected on radiological investigations.
Over 40% of patients in this study started anti-TB treatment before positive culture results were available. This is a reasonable approach, if the patient is symptomatic and the index of suspicion is high, that should be made in partnership with a TB specialist. However, unless there is a clinical indication to start treatment urgently, antibiotics should be witheld until after a biopsy has been performed and samples have been sent for mycobacterial culture. This will maximize the likelihood of growing TB from the sample, which will enable confirmation of the diagnosis and drugsusceptibility testing.
The patient's local TB clinic is responsible for overseeing their anti-TB treatment, which in most cases will be a sixmonth course, 17 and initiating contact tracing. In this study, there was variation in how and when patients were referred to TB services. The numbers are too small to make a meaningful comparison, but where the diagnosis of TB is confirmed, we recommend referring patients directly to a local TB service to avoid unnecessary delays.
This study has limitations. It was conducted in a tertiary centre that receives United Kingdom-wide referrals, so it manages more patients with bone and joint TB than most centres. Its role as a sarcoma centre probably distorts the case-mix, as seen with the under-representation of spinal TB, but many of our findings and recommendations will be applicable to general orthopaedic units.
Most patients had been symptomatic for months before referral. Unfortunately, there were insufficient data to establish how this time was spent. If it is attributable to time in primary or local secondary care, additional training of general practitioners and hospital doctors might be beneficial. There was insufficient information to establish why some patients with suspected bone and joint TB did not start treatment until after the results of the culture were available.
Myco-bacterial culture is not 100% sensitive. 13 Nationally, 45.9% of extra-pulmonary TB cases are culturepositive compared with 72.7% of pulmonary cases.
1 Our study includes only patients with culture-positive bone and joint TB, and therefore misses those treated presumptively without positive cultures. Many patients seen at our centre are referred both to and from other hospitals, and their ultimate diagnosis is not always available locally. As we could not reliably capture this group, they were not included in this study.
As with any retrospective study, some data are incomplete despite our best efforts. However, we are confident that our Winpath system search captured all cases of culture-positive bone and joint TB diagnosed during the study period.
In conclusion, patients with bone and joint TB typically wait several months for diagnosis and treatment and some of these delays are avoidable. The non-specific presentation of this condition means that an index of suspicion must be maintained to avoid missing cases, particularly in high-risk patients (young, male, recent migrants) with bone and joint pathology. Myco-bacterial culture of biopsy specimens is crucial for diagnosis and drug-susceptibility testing, and should be performed in any patient for whom infection or malignancy is being considered, or when there is clinical uncertainty. Early involvement of an infection specialist is recommended. They can advise on and expedite microbiological testing and access specialist diagnostic tests such as Xpert MTB/RIF. The use of rapid diagnostic tests such as Xpert significantly speeds up diagnosis and starting anti-TB treatment. They can also advise on treatment and facilitate engagement with local TB services. When the diagnosis is made, the managing team should refer the patient directly to the local TB service.
Take home message:
-Patients with bone and joint tuberculosis experience monthslong delays in diagnosis and treatment. -To minimize these delays, knowledge of patient demographics, clinical features and key diagnostic tests are essential.
